3SD-31270-12359
2 vaccinations
1 coded response
13 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 565 / MN
- Registered
- 2021-04-02
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-31
Dose 1 — Pfizer-BioNTech
-
2021-04-02
Registered in v-safe
- 2021-04-02
- 2021-04-04
- 2021-04-07
-
2021-04-21
Dose 2 — Pfizer-BioNTech
- 2021-04-21
- 2021-04-22
- 2021-04-23
- 2021-04-26
- 2021-04-27
- 2021-04-30
- 2021-05-26
- 2021-06-02
- 2021-10-20
-
2022-04-21
Survey response — 12 months, dose 2MedDRA: Headache, Nasopharyngitis, Pain — Feeling: Poor · Be unable to work or attend schoolFree text: Bad head cold, headache, body achesMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-31 | Pfizer-BioNTech | |
| 2 | 2021-04-21 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Bad head cold, headache, body aches
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Pain | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release